source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Seeking Alpha | 2021-04-21 08:24:11 | https://seekingalpha.com/article/4420219-lilium-stock-what-to-like-and-not-to-like | Lilium: What To Like And Not To Like | Lilium: What To Like And Not To Like | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-16 13:38:30 | https://seekingalpha.com/article/4414294-electric-aircraft-evtol-stocks-may-soar | Electric aircraft companies like Archer (ACIC) and Joby Aviation (RTP) could be very successful in the long term, but not all competitors in this race are equally positioned. Regardless of the recent allegations by Wolfpack Research, EHang (EH) has not demonstrated any technology leadership relevant to electric air tax... | Electric Aircraft Stocks May Be Set To Soar, But Not All Are Created Equal | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-08 16:23:00 | https://www.fool.com/investing/2021/03/08/why-atlas-crest-investment-stock-gained-151-in-feb/ | The SPAC got a lift after announcing its acquisition target. | Why Atlas Crest Investment Stock Gained 15.1% in February | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-02-23 14:43:00 | https://www.globenewswire.com/news-release/2021/02/23/2180864/0/en/UPDATE-Archer-Announces-Commitment-to-Launching-Its-Urban-Air-Mobility-Network-In-Los-Angeles-by-2024.html | PALO ALTO, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- California-based Archer, who are designing and developing electric vertical takeoff and landing aircraft (eVTOL), today announced their commitment to launching their first Urban Air Mobility (UAM) network in Los Angeles by 2024. Archer is excited to explore the poten... | UPDATE - Archer Announces Commitment to Launching Its Urban Air Mobility Network In Los Angeles by 2024 | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-02-23 07:00:00 | https://www.globenewswire.com/news-release/2021/02/23/2180280/0/en/Archer-Announces-Commitment-to-Launching-Its-Urban-Air-Mobility-Network-in-Los-Angeles-by-2024.html | PALO ALTO, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- California-based Archer, who are designing and developing electric vertical takeoff and landing aircraft (eVTOL), today announced their commitment to launching their first Urban Air Mobility (UAM) network in Los Angeles by 2024. Archer is excited to explore the poten... | Archer Announces Commitment to Launching Its Urban Air Mobility Network in Los Angeles by 2024 | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-02-16 12:10:00 | https://seekingalpha.com/article/4406322-archer-aviation-promising-future-in-urban-air-mobility-market-but-aggressive-valuation | Archer Aviation: Promising Future, Aggressive Valuation | Archer Aviation: Promising Future, Aggressive Valuation | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-02-10 16:25:03 | https://pulse2.com/acic-stock-price-nyse-atlas-crest-investment-corp-increased-22-47-why-it-happened/ | The stock price of Atlas Crest Investment Corp (NYSE: ACIC) increased by 22.47%. This is why it happened. | ACIC Stock Price Increased 22.47%: Why It Happened | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-02-10 14:05:00 | https://www.marketwatch.com/story/archer-aviation-gets-a-1-billion-order-from-united-airlines-on-the-same-day-it-announces-a-deal-to-go-public-11612983906 | Archer Aviation Inc. said Wednesday that United Airlines Holdings Inc. placed a $1 billion order for its all-electric vertical take-off and landing aircraft (eVTOL), on the same day the company announced a deal that will allow the public to invest in the urban air mobility (UAM) company in the coming months. | Archer Aviation gets a $1 billion order from United Airlines, on the same day it announces a deal to go public | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-10 11:53:00 | https://www.fool.com/investing/2021/02/10/why-shares-of-atlas-crest-investment-are-soaring-t/ | The SPAC is merging with an aerospace start-up that has some big-name backers. | Why Shares of Atlas Crest Investment Are Soaring Today | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-10 11:00:00 | https://www.fool.com/investing/2021/02/10/electric-airplane-startup-archer-goes-public-with/ | The company is merging with a SPAC to access public markets. | Electric Airplane Start-Up Archer Going Public With Assist From United Airlines | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-02-10 10:21:04 | https://investorplace.com/2021/02/acic-stock-13-things-to-know-about-atlas-crest-and-the-archer-spac-merger/ | ACIC stock is on the move today on news that Atlas Crest is behind the Archer SPAC merger. Here's what to know about the aviation play. | ACIC Stock: 13 Things to Know About Atlas Crest and the Archer SPAC Merger | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-10 10:19:59 | https://www.benzinga.com/m-a/21/02/19587718/urban-air-mobility-archer-lands-spac-merger-1b-united-airlines-purchase-order-what-investors-should | Urban air mobility company Archer has found a SPAC deal to bring its electric vertical takeoff and landing vehicle — eVTOL — to market. The SPAC Deal: Urban air mobility company Archer is going public in a SPAC merger with Atlas Crest Investment Corp (NYSE: ACIC). | Urban Air Mobility Archer Lands SPAC Merger, $1B United Airlines Purchase Order: What Investors Should Know | ACIC | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-30 15:13:07 | https://www.fool.com/investing/2023/06/30/why-shares-of-ac-immune-sa-jumped-this-week/ | AC Immune is a clinical-stage biotech with 16 programs in its pipeline. It is attempting to develop an Alzheimer's disease vaccine. | Why Shares of AC Immune Jumped This Week | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PennyStocks | 2023-06-28 06:50:00 | https://pennystocks.com/featured/2023/06/28/trading-penny-stocks-with-limited-capital-3-tops-tips/ | The allure of penny stocks is undeniable. Their low price and potential for massive returns create an inviting landscape for individuals, especially those with limited capital, to take a leap into the world of investing. | Trading Penny Stocks With Limited Capital: 3 Tops Tips | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-06-27 07:52:00 | https://www.marketwatch.com/story/ac-immunes-stock-soars-13-after-fda-grants-fast-track-designation-to-alzheimers-treatment-521c54b2 | AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track designation for an Alzheimer's disease treatment. The treatment, called ACI-24.060, is an anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate. | AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2023-03-20 08:00:00 | https://www.globenewswire.com/news-release/2023/03/20/2630182/0/en/AC-Immune-at-AD-PD-2023-to-Present-New-Clinical-and-Preclinical-Data-from-its-Precision-Medicine-Pipeline.html | AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline | AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-18 09:00:00 | https://seekingalpha.com/article/4588361-ac-immune-dementia-focused-swiss-biotech-with-sad-history-failures | ACIU is a leading researcher in the field of dementia, with major deals with big pharma. Unfortunately, AD is a tough space and none of its molecules have turned out well so far. | AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2023-03-08 07:00:00 | https://www.globenewswire.com/news-release/2023/03/08/2622870/0/en/AC-Immune-to-Report-Full-Year-2022-Financial-Results-and-Provide-Corporate-Update-on-March-16-2023.html | AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 | AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2023-02-02 08:15:00 | https://www.globenewswire.com/news-release/2023/02/02/2600439/0/en/AC-Immune-to-Present-at-the-SVB-Securities-Global-Biopharma-Conference.html | AC Immune to Present at the SVB Securities Global Biopharma Conference | AC Immune to Present at the SVB Securities Global Biopharma Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-12-27 13:02:46 | https://seekingalpha.com/article/4566572-ac-immune-tax-loss-selling-opportunity | ACIU has recently fallen due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand and yet it has numerous programs in clinic and prestigious partners. | Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-11-23 07:30:00 | https://www.globenewswire.com/news-release/2022/11/23/2561536/0/en/AC-Immune-to-Present-Progress-of-Alzheimer-s-Disease-Programs-targeting-Abeta-and-Tau-at-the-15th-CTAD-Conference.html | Lausanne, Switzerland, November 2 3 , 202 2 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candi... | AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-28 10:11:42 | https://www.zacks.com/stock/news/1959431/ac-immune-aciu-reports-q2-loss-lags-revenue-estimates | AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? | AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-06-16 06:39:51 | https://www.marketwatch.com/story/ac-immune-shares-slide-15-premarket-after-trial-of-alzheimers-treatment-misses-its-main-goals-2022-06-16 | Shares of biotech AC Immune SA ACIU, -9.21% slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer's disease failed to slow or prevent cognitive decline in patients with a specific genetic mutation that causes early-onset disease. The trial involved 252 people who are member... | AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-05-31 07:30:00 | https://www.globenewswire.com/news-release/2022/05/31/2453131/0/en/AC-Immune-to-Present-at-the-2022-Jefferies-Healthcare-Conference.html | LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jeffe... | AC Immune to Present at the 2022 Jefferies Healthcare Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-04-27 07:55:00 | https://www.globenewswire.com/news-release/2022/04/27/2430131/0/en/AC-Immune-to-Present-at-the-B-Riley-Annual-Neuro-Ophthalmology-Virtual-Investor-Conference.html | LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the B.Riley ... | AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-02-28 07:30:00 | https://www.globenewswire.com/news-release/2022/02/28/2393048/0/en/AC-Immune-to-Present-at-the-AD-PD-2022-New-Clinical-and-Preclinical-Data-for-Alpha-Synuclein-Abeta-and-TDP-43-Programs.html | Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM ) | AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-02-15 14:54:13 | https://www.benzinga.com/general/biotech/22/02/25641659/ac-immune-janssen-partnered-alzheimers-vaccine-shows-tau-specific-antibodies-in-early-stage-trial | AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for ACI-35.030 come from the high-dose group in P... | AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-02-02 08:58:00 | https://www.globenewswire.com/news-release/2022/02/02/2377675/0/en/AC-Immune-to-Present-at-the-SVB-Leerink-11th-Annual-Global-Healthcare-Conference.html | LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the SVB Leeri... | AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-11-08 10:01:12 | https://www.zacks.com/stock/news/1824936/ac-immune-aciu-reports-q3-loss-misses-revenue-estimates | AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? | AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-11-08 09:12:16 | https://pulse2.com/ac-immune-nasdaq-aciu-stock-why-the-price-increased-today/ | The stock price of AC Immune SA (NASDAQ: ACIU) increased over 9% pre-market today. This is why it happened. | AC Immune (ACIU) Stock: Why The Price Increased Today | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-11-05 16:48:11 | https://www.zacks.com/stock/news/1824688/earnings-preview-ac-immune-aciu-q3-earnings-expected-to-decline | AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-10-25 07:00:00 | https://www.globenewswire.com/news-release/2021/10/25/2319687/0/en/AC-Immune-to-Present-at-the-Jefferies-London-Healthcare-Conference.html | LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual p... | AC Immune to Present at the Jefferies London Healthcare Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-09-16 14:54:26 | https://www.gurufocus.com/news/1525463/alzheimers-drug-for-roche-partner-ac-immune-shows-promise | The ardor for shares of AC Immune SA ( ACIU , Financial) has cooled considerably since the company's Aug. 31 announcement of somewhat promising study results for its Alzheimer's drug. The Swiss biotech's stock shot up to a 52-week high of $12.61, but has since been halved as investors questioned how meaningful the tria... | Alzheimer's Drug for Roche Partner AC Immune Shows Promise | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-09-03 07:52:00 | https://www.globenewswire.com/news-release/2021/09/03/2291403/0/en/AC-Immune-CEO-Andrea-Pfeifer-Receives-First-SEF-WomenAward-for-CEO-of-the-Year.html | LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and CEO Andrea Pfeifer has been awarded by the Swiss Economic Forum (SEF) with the SE... | AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-09-02 07:00:00 | https://www.globenewswire.com/news-release/2021/09/02/2290709/0/en/AC-Immune-to-Participate-in-Upcoming-Virtual-Investor-Conferences-in-September.html | LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences: | AC Immune to Participate in Upcoming Virtual Investor Conferences in September | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-01 13:47:05 | https://www.zacks.com/stock/news/1789781/ac-immune-s-aciu-stock-up-despite-mixed-data-from-ad-study | AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16% | AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-08-31 15:40:01 | https://www.benzinga.com/analyst-ratings/analyst-color/21/08/22744669/what-leerink-wainwright-have-to-say-for-this-alzheimers-focused-firm | Earlier today, AC Immune SA (NASDAQ:ACIU) announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial. SVB Leerink notes that semorinemab data is "good news. | What Leerink, Wainwright Have To Say For This Alzheimer's Focused Firm | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-08-31 12:30:06 | https://investorplace.com/2021/08/aciu-stock-the-big-alzheimers-news-that-has-ac-immune-skyrocketing-today/ | AC Immune (ACIU) stock is rising higher on Tuesday after revealing positive results from a recent Alzheimer's disease study. The post ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today appeared first on InvestorPlace. | ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-31 11:06:02 | https://www.fool.com/investing/2021/08/31/heres-why-ac-immune-stock-is-surging-today/ | MIxed results for the company's Alzheimer's disease candidate are good enough for the market today. | Here's Why AC Immune Stock Is Surging Today | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Schaeffers Research | 2021-08-31 10:51:55 | https://www.schaeffersresearch.com/content/news/2021/08/31/biopharmaceutical-stock-blasts-higher-on-alzheimers-treatment-update | The shares of Switzerland-based biopharmaceutical company AC Immune SA (NASDAQ:ACIU) are soaring this morning, up 72.4% to trade at $12.04 at last check. | Biopharmaceutical Stock Blasts Higher on Alzheimer's Treatment Update | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-08-31 08:27:07 | https://pulse2.com/ac-immune-nasdaq-aciu-stock-over-65-increase-pre-market-explanation/ | The stock price of AC Immune SA (NASDAQ: ACIU) increased by over 65% pre-market. This is why it happened. | ACIU Stock: Over 65% Increase Pre-Market Explanation | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-08-31 07:30:00 | https://www.globenewswire.com/news-release/2021/08/31/2289102/0/en/AC-Immune-Announces-First-Positive-Cognitive-Results-for-a-Tau-Targeting-Monoclonal-Antibody-in-Alzheimer-s-Disease.html | Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 | AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-08-04 09:55:35 | https://www.zacks.com/stock/news/1774069/ac-immune-aciu-reports-q2-loss-lags-revenue-estimates | AC Immune (ACIU) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? | AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-08-04 07:00:00 | https://www.globenewswire.com/news-release/2021/08/04/2274391/0/en/AC-Immune-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html | Announced strategic acquisition of industry-leading Parkinson's disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE | AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-07-29 07:30:00 | https://www.globenewswire.com/news-release/2021/07/29/2271165/0/en/AC-Immune-Presents-Full-Phase-1b-Results-on-Anti-Abeta-Vaccine-and-Discusses-its-First-in-Class-Diagnostic-for-Parkinson-s-Disease-at-AAIC-2021.html | ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) | AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson's Disease at AAIC 2021 | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-07-27 09:27:52 | https://www.benzinga.com/general/biotech/21/07/22170704/ac-immune-secures-funding-from-biontech-investors-buys-parkinsons-vaccine-candidate | AC Immune SA (NASDAQ: ACIU) has gained a multi-million investment from the principal backers of BioNTech SE (NASDAQ: BNTX) while acquiring a possible Parkinson's disease vaccine. It announced a $25 million private share placement with a group of investors led by Athos Service GmbH. | AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-07-27 08:00:00 | https://www.globenewswire.com/news-release/2021/07/27/2269379/0/en/AC-Immune-acquires-AFFiRiS-Specific-Active-Immunotherapy-SAIT-anti-alpha-synuclein-programs-targeting-neurodegenerative-diseases.html | VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering preci... | AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-07-27 07:30:00 | https://www.globenewswire.com/news-release/2021/07/27/2269302/0/en/AC-Immune-Announces-Strategic-Acquisition-of-Industry-leading-Parkinson-s-Disease-Vaccine-Candidate-and-Equity-Investment-Led-by-Athos-Service-GmbH.html | All-stock transaction maintains AC Immune's strong cash position | AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-06-25 08:38:00 | https://www.globenewswire.com/news-release/2021/06/25/2253252/0/en/AC-Immune-Holds-its-Annual-General-Meeting-of-Shareholders.html | LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that AC Immune held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independe... | AC Immune Holds its Annual General Meeting of Shareholders | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-06-02 07:58:03 | https://pulse2.com/aciu-stock-price-over-20-increase-pre-market-explanation/ | The stock price of AC Immune SA (NASDAQ: ACIU) increased by over 20% pre-market. This is why it happened. | ACIU Stock Price: Over 20% Increase Pre-Market Explanation | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-06-02 07:34:20 | https://www.benzinga.com/general/biotech/21/06/21385753/ac-immune-stock-jumps-after-alzheimers-disease-vaccine-candidate-confirms-favorable-safety-tolera | AC Immune SA (NASDAQ: ACIU) has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimer's disease (AD). No safety concerns or evidence for CNS inflammation or ARIA (amyloid-related imaging abnormalities) were observed, confirmi... | AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-05-20 07:00:00 | https://www.globenewswire.com/news-release/2021/05/20/2233221/0/en/AC-Immune-to-Highlight-First-in-Class-Alzheimer-s-Disease-Vaccine-Programs-at-Upcoming-Investor-Conferences.html | LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conf... | AC Immune to Highlight First-in-Class Alzheimer's Disease Vaccine Programs at Upcoming Investor Conferences | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-05-17 09:55:02 | https://www.benzinga.com/general/biotech/21/05/21149229/ac-immune-provides-update-on-alzheimers-disease-vaccine-candidate | AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease (AD). The trial expansion specifically includes vaccination of additional AD patients at the... | AC Immune Provides Update On Alzheimer's Disease Vaccine Candidate | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-28 09:17:05 | https://www.zacks.com/stock/news/1466732/ac-immune-aciu-reports-q1-loss-misses-revenue-estimates | AC Immune (ACIU) delivered earnings and revenue surprises of -19.05% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock? | AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-04-28 07:00:00 | https://www.globenewswire.com/news-release/2021/04/28/2218459/0/en/AC-Immune-Reports-First-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html | LAUSANNE, Switzerland, April 28, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2021. The Company also provided an overview of its recent c... | AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-03-31 16:30:00 | https://www.globenewswire.com/news-release/2021/03/31/2202884/0/en/AC-Immune-Appoints-Experienced-Biotech-and-Investment-Executive-Dr-Alan-Colowick-to-Board-of-Directors.html | Dr. Colowick has more than 20 years of experience in large and emerging biotech companies | AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-03-31 07:00:00 | https://www.globenewswire.com/news-release/2021/03/31/2202245/0/en/AC-Immune-Hosts-Investor-Webinar-Highlighting-the-Power-of-its-Morphomer-Platform-to-Enable-Precision-Medicine-for-Neurodegenerative-Disease.html | Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics | AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-03-26 07:00:00 | https://www.globenewswire.com/news-release/2021/03/26/2199963/0/en/AC-Immune-to-Host-Webinar-Highlighting-its-Innovative-Morphomer-Technology-Platform-and-Pipeline.html | Therapeutic and diagnostic Morphomers™ enable AC Immune's unique precision medicine approach for neurodegenerative diseases | AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-26 06:45:04 | https://seekingalpha.com/article/4416238-ac-immune-old-theory-new-company | ACIU is developing drugs for Alzheimer's disease. | AC Immune: Old Theory, New Company | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-03-23 08:01:40 | https://www.benzinga.com/news/earnings/21/03/20294749/recap-ac-immune-q4-earnings | Shares of AC Immune (NASDAQ:ACIU) moved higher by 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to ($0.28), which missed the estimate of ($0.27). | Recap: AC Immune Q4 Earnings | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-03-16 10:52:09 | https://www.benzinga.com/general/biotech/21/03/20188489/why-can-fite-moderna-ac-immune-shares-are-rallying | Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday. | Why Can-Fite, Moderna, AC Immune Shares Are Rallying | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-03-09 07:00:00 | https://www.globenewswire.com/news-release/2021/03/09/2189366/0/en/AC-Immune-Presents-New-Preclinical-Data-for-Therapeutic-and-Diagnostic-Candidates-Addressing-Novel-Targets-for-Neurodegenerative-Diseases.html | Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43 | AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-02-11 20:24:00 | https://www.fool.com/investing/2021/02/11/why-ac-immune-stock-surged-today/ | Researchers are excited about the potential of the biotech's investigational Alzheimer's vaccine. | Why AC Immune Stock Surged Today | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-02-11 10:14:41 | https://investorplace.com/2021/02/aciu-stock-why-ac-immune-shares-are-rocketing-higher-today/ | Swiss biopharma AC Immune has released positive updates this week on both its Alzheimer's and Parkinson's disease treatments. Investors are piling in to ACIU stock. | ACIU Stock: Why AC Immune Shares Are Rocketing Higher Today | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-02-11 07:40:34 | https://pulse2.com/aciu-stock-price-nasdaq-ac-immune-sa-increases-over-130-pre-market-why-it-happened/ | The stock price of AC Immune SA (NASDAQ: ACIU) is trading at over 130% pre-market. This is why it happened. | ACIU Stock Price Increases Over 130% Pre-Market: Why It Happened | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-02-11 07:00:00 | https://www.globenewswire.com/news-release/2021/02/11/2173941/0/en/AC-Immune-s-Alzheimer-s-Vaccine-Generates-Potent-Anti-pTau-Antibody-Response-in-a-Phase-1b-2a-Study.html | Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer's disease | AC Immune's Alzheimer's Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-02-08 07:00:00 | https://www.globenewswire.com/news-release/2021/02/08/2171227/0/en/AC-Immune-Initiates-Clinical-Study-of-First-in-class-Diagnostic-for-Parkinson-s-Disease.html | LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that the first patient has been scanned in a first-in-human study of its novel diagnostic agent for P... | AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson's Disease | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-01-29 07:00:00 | https://www.globenewswire.com/news-release/2021/01/29/2166528/0/en/AC-Immune-Reports-Progress-for-Therapeutic-Programs-Targeting-the-NLRP3-Inflammasome-Pathway.html | Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors | AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2020-12-15 08:00:00 | https://www.globenewswire.com/news-release/2020/12/15/2145282/0/en/AC-Immune-Receives-Competitive-Target-ALS-Foundation-Grant-to-Accelerate-the-Development-of-Proprietary-Phosphorylated-TDP-43-Immuno-assay.html | Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital | AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2020-11-20 08:40:00 | https://www.globenewswire.com/news-release/2020/11/20/2130979/0/en/Immunotherapy-Pioneer-Prof-Carl-H-June-Joins-AC-Immune-s-Board-of-Directors.html | Prof. June is a world authority on immune tolerance and adoptive immunotherapy | Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune's Board of Directors | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2020-11-18 07:00:00 | https://www.globenewswire.com/news-release/2020/11/18/2129052/0/en/Neurologist-and-Psychiatrist-Prof-Johannes-Rolf-Streffer-MD-Joins-AC-Immune-SA-as-Chief-Medical-Officer.html | Prof. Streffer is a n established authority on n euroscience and b iomarker modalities | Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2020-11-13 07:27:45 | https://www.benzinga.com/news/earnings/20/11/18357378/ac-immune-q3-earnings-insights | Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat the estimate of ($0.28). | AC Immune: Q3 Earnings Insights | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2020-11-13 07:00:00 | https://www.globenewswire.com/news-release/2020/11/13/2126374/0/en/AC-Immune-Reports-Q3-2020-Financial-Results-and-Provides-Business-Update.html | LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for Q3 2020 and provided a business update. The Company ended the third quarter wit... | AC Immune Reports Q3 2020 Financial Results and Provides Business Update | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2020-11-09 04:00:00 | https://www.globenewswire.com/news-release/2020/11/09/2122421/0/en/AC-Immune-and-WuXi-Biologics-Strengthen-Strategic-Partnership-to-Accelerate-AC-Immune-s-Anti-TDP-43-Antibodies-into-Clinical-Development.html | Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development | AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune's Anti-TDP-43 Antibodies into Clinical Development | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-10-30 04:44:35 | https://seekingalpha.com/article/4383009-ac-immunes-alzheimers-setback-and-news-good-bad-and-ugly-of-biopharma | AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer. | AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-07 14:53:02 | https://finance.yahoo.com/news/aerie-aeri-q2-earnings-miss-145302253.html | Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020. | Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-06 16:00:04 | https://finance.yahoo.com/news/know-ac-immune-aciu-rating-160004409.html | AC Immune (ACIU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-05 15:25:03 | https://finance.yahoo.com/news/ac-immune-aciu-reports-q2-152503879.html | AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock? | AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-05 11:00:00 | https://finance.yahoo.com/news/ac-immune-reports-q2-2020-110000399.html | * Substantial progress achieved across three anti-Tau clinical development programs; all clinical and preclinical programs remain on track to generate value in the second half of 2020 * Top line Phase 2 data expected in the second half of 2020 for anti-Tau antibody semorinemab * CHF 262.5 million in cash ensures oper... | AC Immune Reports Q2 2020 Financial Results and Provides Business Update | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-03 11:00:00 | https://finance.yahoo.com/news/ac-immune-initiates-ind-enabling-110000388.html | First-in-class TDP-43 antibody developed using SurpraAntigen™ platform The only TDP-43 antibody with reported in vivo activity LAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerati... | AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-30 11:55:00 | https://finance.yahoo.com/news/ac-immune-wins-prestigious-award-115500446.html | AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical results presented at AAIC on the Company’s alpha-synuclein positron emission tomography -(PET) tracer program Further validates th... | AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-28 11:00:00 | https://finance.yahoo.com/news/ac-immune-demonstrates-enhanced-performance-110000701.html | Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform for generating highly selective small molecule diagnostics LAUSANNE, Switzerland, July 28, 2020 (GLOBE NEWSWIRE) -- AC Imm... | AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-23 11:00:00 | https://finance.yahoo.com/news/ac-immune-present-advances-two-110000679.html | Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseasesLAUSANNE, Switzerland, July 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurode... | AC Immune to Present Advances in Two of the Company’s World Leading Programs at the Upcoming Alzheimer’s Association International Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-17 14:04:02 | https://finance.yahoo.com/news/ac-immune-advances-alzheimers-vaccine-140402756.html | AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study. | AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-07-17 12:51:59 | https://seekingalpha.com/article/4359073-principia-sanofi-rumors-and-news-good-bad-and-ugly-of-biopharma | Principia up on Sanofi interest rumors. Qiagen N.V. | Principia Sanofi Rumors, And Other News: The Good, Bad And Ugly Of Biopharma | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-17 11:41:01 | https://finance.yahoo.com/news/daily-biotech-pulse-2-ipos-114101647.html | Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) * AC Immune SA (NASDAQ: ACIU) ( announced clinical trial update for its Alzheimer's vaccine candidate) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. Class... | The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-16 19:01:00 | https://finance.yahoo.com/m/4a84e68a-aef5-34b5-9585-f081f1665695/here%26%2339%3Bs-why-ac-immune.html | Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted. | Here's Why AC Immune Jumped Higher Today | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-16 17:21:20 | https://finance.yahoo.com/m/3f30212c-3f78-3640-88a3-795c1dc1f717/ac-immune-stock-catapults-to.html | AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment. The drug will be tested over 48 weeks in early-stage patients. | AC Immune Stock Catapults To Two-Year High On Alzheimer's News | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-16 12:29:12 | https://finance.yahoo.com/news/ac-immune-explodes-56-pre-122912183.html | Shares in AC Immune (ACIU) are surging 56% in Thursday’s pre-market trading after the biopharma announced the initiation of the second highest dosing group in the its Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer’s disease (AD).The decision to advance to the higher dosing group follows... | AC Immune Explodes 56% In Pre-Market On Alzheimer Study Initiation | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-16 11:00:10 | https://finance.yahoo.com/news/ac-immune-advances-phospho-tau-110010317.html | Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35.030 is a clinical stage vaccine generated. | AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase 1b/2a Study | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-07 13:00:36 | https://finance.yahoo.com/news/tau-pet-tracer-pi-2620-130036315.html | BERLIN and LAUSANNE, Switzerland, July 07, 2020 -- Life Molecular Imaging and AC Immune SA (NASDAQ: ACIU) announce the publication of clinical data of the investigational. | Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-07 10:51:18 | https://finance.yahoo.com/news/much-ac-immune-sa-nasdaq-105118382.html | A look at the shareholders of AC Immune SA (NASDAQ:ACIU) can tell us which group is most powerful. Institutions often... | How Much Of AC Immune SA (NASDAQ:ACIU) Do Insiders Own? | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-07-04 18:59:33 | https://finance.yahoo.com/news/hedge-funds-never-bullish-ac-185933286.html | The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […] | Hedge Funds Have Never Been This Bullish On AC Immune SA (ACIU) | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-06-26 11:21:11 | https://finance.yahoo.com/news/ac-immune-announces-results-annual-112111174.html | AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced AC Immune shareholders approved all of the resolutions as proposed by the Board of Directors at today's Annual General Meeting (AGM) in Lausanne. At the AGM, shareholders ... | AC Immune Announces Results of Annual General Meeting | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-05-15 11:00:10 | https://finance.yahoo.com/news/ac-immune-ceo-showcase-novel-110010444.html | LAUSANNE, Switzerland, May 15, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative. | AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-05-06 14:12:22 | https://finance.yahoo.com/news/ac-immune-sa-nasdaq-aciu-141222141.html | As you might know, AC Immune SA (NASDAQ:ACIU) just kicked off its latest quarterly results with some very strong... | AC Immune SA (NASDAQ:ACIU) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-05-04 12:35:12 | https://finance.yahoo.com/news/ac-immune-aciu-reports-q1-123512231.html | AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock? | AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-05-04 11:00:10 | https://finance.yahoo.com/news/ac-immune-reports-q1-2020-110010543.html | On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19Ongoing strong financial position with CHF 277.9 million in. | AC Immune Reports Q1 2020 Financial Results and Provides Business Update | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
YAHOO | 2020-04-28 15:16:09 | https://finance.yahoo.com/news/axsome-shares-jump-25-alzheimers-151609077.html | Clinical trial of AX-05 showed drug reduces patient agitation Continue reading... | Axsome Shares Jump 25% on Alzheimer's Study Results | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GURUFOCUS | 2020-04-28 14:38:26 | https://www.gurufocus.com/news/1118254/axsome-shares-jump-25-on-alzheimers-study-results | Axsome Shares Jump 25% on Alzheimer’s Study Results, Stocks: AXSM,LLY,RHHBY,ACIU,MOR,ESALY,BIIB, release date:Apr 27, 2020 | Axsome Shares Jump 25% on Alzheimer€™s Study Results | ACIU | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.